US 12,344,613 B2
EGFR inhibitor for the treatment of cancer
Cosimo Dolente, Allschwil (CH); Annick Goergler, Colmar (FR); David Hewings, Basel (CH); Georg Jaeschke, Basel (CH); Bernd Kuhn, Reinach (CH); Yvonne Alice Nagel, Basel (CH); Christa Ulrike Obst-Sander, Reinach BL (CH); Antonio Ricci, Biel-Benken (CH); Daniel Rueher, Raedersdorf (FR); and Sandra Steiner, Sursee (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Appl. No. 17/620,239
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
PCT Filed Jun. 19, 2020, PCT No. PCT/EP2020/067076
§ 371(c)(1), (2) Date Dec. 17, 2021,
PCT Pub. No. WO2020/254562, PCT Pub. Date Dec. 24, 2020.
Claims priority of application No. 19181754 (EP), filed on Jun. 21, 2019.
Prior Publication US 2022/0315592 A1, Oct. 6, 2022
Int. Cl. C07D 487/04 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); C07D 519/00 (2013.01)] 10 Claims
 
1. A compound or a pharmaceutically acceptable salt thereof of formula (I)

OG Complex Work Unit Chemistry